Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol vs Salmeterol in Japanese COPD Patients
NCT00876694Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of indacaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoints: Clinically Notable Pulse Rate at 52 weeks, Clinically Notable Systolic Blood Pressure at 52 weeks and 4 more. Started Mar 2009; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00876694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00876694.